drugset
drugset / Trial / NCT04462770

A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome

NCT04462770 ↗

Phase 3 Recruiting 150 enrolled Epygenix Harmony Biosciences Management, Inc. · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a multicenter, Phase 3, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of clemizole hydrochloride (EPX-100) as adjunctive therapy in children and adult participants with Dravet syndrome (DS).

Timeline

Start
2020-09-15
Primary completion
2027-04
Completion
2029-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Clemizole Small molecule — Oral

Indications

Dravet syndrome